We are currently working to resolve technical issues preventing us from processing applications, bookings or payment for membership. Please email Membership on membership@rheumatology.org.uk with any queries.


This register measures effectiveness and safety of Etanercept in children with Juvenile Idiopathic Arthritis (JIA).

Combined with the BCRD study, this forms one of the world's largest groups of children and young people involved in research about JIA.

The study has focused on Etanercept use in JIA treatments, but a parallel group of children with JIA treated with Methotrexate is also recruiting in order to compare side effects and long-term outcomes between the two treatment groups.

The study, previously known as the Biologics and New Drugs Register, moves to The University of Manchester to sit among the other national rheumatic disease biologic registers.

The University of Manchester also oversees the running of the Biologics for Children with Rheumatic Diseases (BCRD) study, which was set up in 2010 and recruits children and young people with JIA who are starting any biologic or biosimilar drug other than Enbrel.

JIA study


Submit enquiry

BCRD study


Submit enquiry